Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats

被引:46
作者
Arnold, JC
Hunt, GE
McGregor, LS
机构
[1] Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia
[2] Univ Sydney, Concord Hosp, Dept Psychol Med, Concord, NSW 2139, Australia
基金
澳大利亚研究理事会; 英国医学研究理事会;
关键词
cannabinoid; intracranial self; stimulation; Lewis rat; CP 55,940; SR; 141716;
D O I
10.1016/S0024-3205(01)01366-2
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Lewis rats were trained to self-stimulate the medial forebrain bundle (MFB) using a rate-frequency paradigm. They were then tested for the effects of the cannabinoid receptor agonist CP 55,940, the selective cannabinoid receptor antagonist SR 141716 and the dopamine D-1 receptor antagonist SCH 23390. CP 55,940 (0, 10, 25 and 50 mug/kg i.p.) had no effect on MFB self-stimulation behaviour as assessed by the M-50, the stimulation frequency at which half-maximal response rates were obtained. With SR 141716, only a very high dose (20 mg/kg i.p.) caused a significant inhibition of the rewarding efficacy of the stimulation. This was seen as an increase in the M-50. All other doses of SR 141716 (0, 1, 3, 10 mg/kg i.p.) were ineffective in modulating the M-50. By comparison, a relatively low dose (0.06 mg/kg i.p.) of SCH 23390 caused a large increase in M-50. These results indicate a relatively modest influence, if any at all, of exogenous or endogenous cannabinoids on reward-relevant neurotransmission. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:97 / 108
页数:12
相关论文
共 47 条
[1]   Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function [J].
Alonso, R ;
Voutsinos, B ;
Fournier, M ;
Labie, C ;
Steinberg, R ;
Souilhac, J ;
Le Fur, G ;
Soubrie, P .
NEUROSCIENCE, 1999, 91 (02) :607-620
[2]   Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors [J].
Arnone, M ;
Maruani, J ;
Chaperon, F ;
Thiebot, MH ;
Poncelet, M ;
Soubrie, P ;
LeFur, G .
PSYCHOPHARMACOLOGY, 1997, 132 (01) :104-106
[3]   Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats [J].
Baldo, BA ;
Koob, GF ;
Markou, A .
JOURNAL OF NEUROSCIENCE, 1999, 19 (24) :11017-11026
[4]  
Bauco P, 1997, J PHARMACOL EXP THER, V283, P1160
[5]  
Bonhaus DW, 1998, J PHARMACOL EXP THER, V287, P884
[6]   A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1 - Evidence for a new model of receptor/ligand interactions [J].
Bouaboula, M ;
Perrachon, S ;
Milligan, L ;
Canat, X ;
RinaldiCarmona, M ;
Portier, M ;
Barth, F ;
Calandra, B ;
Pecceu, F ;
Lupker, J ;
Maffrand, JP ;
LeFur, G ;
Casellas, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (35) :22330-22339
[7]   Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats [J].
Chaperon, F ;
Soubrié, P ;
Puech, AJ ;
Thiébot, MH .
PSYCHOPHARMACOLOGY, 1998, 135 (04) :324-332
[8]   STRAIN-SPECIFIC FACILITATION OF DOPAMINE EFFLUX BY DELTA-9-TETRAHYDROCANNABINOL IN THE NUCLEUS-ACCUMBENS OF RAT - AN INVIVO MICRODIALYSIS STUDY [J].
CHEN, JP ;
PAREDES, W ;
LOWINSON, JH ;
GARDNER, EL .
NEUROSCIENCE LETTERS, 1991, 129 (01) :136-140
[9]   Appetite suppression and weight loss after the cannabinoid antagonist SR141716 [J].
Colombo, G ;
Agabio, R ;
Diaz, G ;
Lobina, C ;
Reali, R ;
Gessa, GL .
LIFE SCIENCES, 1998, 63 (08) :PL113-PL117
[10]  
Compton DR, 1996, J PHARMACOL EXP THER, V277, P586